Regorafenib and Durvalumab for the Treatment of High-Risk Liver Cancer

Inclusion Criteria: * Age \>= 18 years at time of study entry * Body weight \> 30 kg * Patients must have hepatocellular carcinoma (HCC) diagnosis confirmed by histology/cytology or clinically by American Association for Study of liver Diseases (AASLD) criteria in cirrhotic patients * Measurable disease * Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1 * Child Pugh class A * Total bilirubin =\< 1.5 x upper limit of normal (ULN) (obtained =\< 28 days prior to registration) * Alanine aminotransferase (ALT) =\< 5 x ULN (obtained =\< 28 days prior to registration) * Aspartate transaminase (AST) =\< 5 x ULN (obtained =\< 28 days prior to registration) * Prothrombin time (PT)/international normalized ratio (INR)/activated partial thromboplastin time (aPTT) =\< 1.5 x ULN OR if patient is receiving anticoagulant therapy and INR or aPTT is within target range of therapy (obtained =\< 28 days prior to registration) * Creatinine =\< 1.5 x ULN or creatinine clearance \>= 60 mL/min/1.73 m\^2 for patients with creatinine levels \> 1.5 x ULN. Creatinine clearance should be calculated per institutional standard (obtained =\< 28 days prior to registration) * Urinary protein is =\< 1+ on dipstick or routine urinalysis or 24-hour urine demonstrating \< 1 gram of protein (obtained =\< 28 days prior to registration) * Absolute neutrophil count (ANC) \>= 1.0 x 10\^9/Liter (obtained =\< 28 days prior to registration) * Hemoglobin \>= 9 grams/deciliter (obtained =\< 28 d…